Kissei Pharmaceutical Co., Ltd.
KSPHF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.02B
Close$
$-5.24
121.4% downside
Current Fair Value
121.4% downsideOvervalued by 121.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.02 Billion |
|---|---|
| Enterprise Value | $-26,088,987,347.00 |
| Annual dividend | $1.03 |
| Dividend yield | 5.39% |
| Earnings per Share | $333.94 |
| Beta | 0.4 |
| Outstanding Shares | 41,451,945 |
Return
| Return on Equity | 6.16% |
|---|---|
| Return on Assets | 5.22% |
| Return on Invested Capital | 3.91% |
Valuation & Multiples
| P/E Ratio | 11.28 |
|---|---|
| PEG | 300.06 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | 1.32 |
| Enterprise Value to EBIT | 13.36 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
July 31, 2026
EPS Estimate
$0.39
Consensus analyst estimateRevenue Estimate
$138.51 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$0.21
Consensus analyst estimateRevenue Estimate
$138.25 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Kissei Pharmaceutical Co., Ltd.
1,786 employees
CEO: Mutsuo Kanzawa
Kissei Pharmaceutical Co., Ltd. specializes in the discovery, development, production, and commercialization of pharmaceutical products, with a primary focus on the Japanese market. Its marketed pharmaceuticals encompass Urief and Urief ...